Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.46 |
| ▸ | CASP1 | P29466 | 11/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569669 | 0.85 | MMP2 (0.64) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL569863 | 0.85 | MMP2 (0.64) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL569312 | 0.84 | MMP2 (0.64) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL569539 | 0.80 | MMP2 (0.61) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL12496831 | 0.77 | RECQL (0.60) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL570168 | 0.75 | MMP2 (0.60) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL568973 | 0.73 | CA12 (0.49) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL570026 | 0.72 | MMP2 (0.53) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL569548 | 0.72 | MMP2 (0.53) | CA12CA9CA1CA2MMP2 | |
| SCHEMBL569753 | 0.70 | MMP2 (0.52) | CA12CA9CA1CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993544-B2 | Carbamoylphosphonates as inhibitors and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| EP-2393495-B1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RES DEV CO (IL) | 2014-07-23 | — | — | EP | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | MMP9, MMP26, MMP25 | CA12 307/4885CA9 104/4885CA1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.